Comparative Effects of Soft Tissue Mobilization and Pressure Therapy With and Without Dynamic Cupping on on Pain and Disability in Patients With Thoracic Back Pain

November 12, 2026 updated by: Salman Bashir, University of Management and Technology Lahore

Comparison of Sequential Effects of Instrument Assisted Soft Tissue Mobilization and Transverse Oscillatory Pressure With and Without Directional Dynamic Cupping on Pain and Disability in Patients With Thoracic Back Pain

This study aims to compare the sequential effects of Instrument-Assisted Soft Tissue Mobilization (IASTM) and Transverse Oscillatory Pressure (TOP), with and without Directional Dynamic Cupping, in patients with thoracic back pain. The study will evaluate the effectiveness of these treatment approaches in reducing pain, improving functional ability, and minimizing disability during daily activities.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

64

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Punjab Province
      • Lahore, Punjab Province, Pakistan, 54000
        • University of Management & Technology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients 25-45 years with non-specific chronic thoracic back pain
  • Both male and female
  • Mild to moderate thoracic back pain with a NPRS Scale score of 3-6 out 10
  • Thoracic back pain lasting at least 3 months (12 weeks)
  • Pain localized to the thoracic region (T1-T12) without radiating pain
  • Willingness to provide informed consent and attend all treatment sessions

Exclusion Criteria:

  • Diagnosed spinal pathological conditions like disc herniation, stenosis
  • Presence of tumors, lung diseases, visceral diseases, or with red flag
  • Referred pain associated with cervical or lumbar radiculopathy
  • History of cardiorespiratory disease
  • History of thoracic surgery or rib fracture fixation within the past 6 months
  • Bleeding disorders or current use of anticoagulant medications
  • Skin infection or hypersensitivity at the treatment area
  • Pregnancy
  • Body Mass Index (BMI) greater than 35 kg/m²

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Instrument assisted soft tissue (IASTM), Transvers oscillatory pressure (TOP)

Participants will receive Instrument-Assisted Soft Tissue Mobilization (IASTM) and Transverse Oscillatory Pressure (TOP) in sitting or prone positions, combined with alternating 10-second resisted isometric trunk flexion-extension contractions. Conventional therapy includes a hot pack for 10 minutes and muscle stretching (10 repetitions, 30-second hold each).

Experimental: Instrument assisted soft tissue, Transvers oscillatory pressure and Directional dynamic cupping

Participants will receive a moist hot pack over the thoracic region for 10-15 minutes, followed by IASTM using the Graston tool for 5-8 minutes.

Transverse Oscillatory Pressure (TOP) will be applied for 3-5 minutes per affected segment, according to patient tolerance.

Directional Dynamic Cupping will then be performed over the thoracic paraspinal muscles for 5-10 minutes with controlled suction and gliding movements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Numerical Pain Rating Scale
Time Frame: Baseline , 2 weeks and 4 weeks post treatment

The 11-point numeric with 0 representing No pain, 1-3 representing Mild Pain (nagging, annoying, interfering little with ADLs), 4-6 representing Moderate Pains (interferes significantly with ADLs), 7-10 representing Sever Pain (disabling, unable to perform ADLs).

Baseline , 2 weeks and 4 weeks post treatment
Function Rating Index
Time Frame: Baseline , 2 weeks and 4 weeks post treatment

The Functional Rating Index (FRI) consists of 10 items: pain intensity, pain frequency, sleep, personal care, travel, work, leisure activities, lifting, walking, and standing. Two items assess pain characteristics, while eight assess spinal functional limitations in daily activities. Each item is scored from 0 (no pain/full function) to 4 (maximum pain/total disability), with higher scores indicating greater disability.

Baseline , 2 weeks and 4 weeks post treatment
Bubble Inclinometer
Time Frame: Baseline , 2 weeks and 4 weeks post treatment

Lumbar range of motion (ROM) will be measured in standing using bubble inclinometers, with S1 and T12 as reference points for flexion and extension, and T12 for lateral flexion.

Two inclinometers will assess forward flexion, while one will assess extension and lateral flexion; actual flexion and extension ROM will be calculated by subtracting the lower inclinometer reading from the upper reading.

Baseline , 2 weeks and 4 weeks post treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

October 20, 2026

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

October 17, 2026

First Submitted That Met QC Criteria

October 17, 2026

First Posted (Actual)

October 23, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The result data collected de-identified individual participant data will be shared.

IPD Sharing Time Frame

Six months after the publication of the manuscript.

IPD Sharing Access Criteria

Data can be requested from the corresponding author.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe